Drug Trial Radar · NCT00658775
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Last checked: Nov 20, 2026Latest source record: Dec 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,069
Actual
Start
Feb 2008
Primary completion
Sep 2009
Study completion Jan 2010
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Apr 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).
Conditions
- Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodiumDrug
Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
EsomeprazoleDrug
Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 WeeksTime frame: Baseline and Week 8
- Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 WeeksTime frame: Baseline and Week 4
Locations
83 sites in 14 countries. Site status is shown where the registry gives one.
Site not named
Moline, Illinois
Site not named
La Plata, Argentina, Argentina
Site not named
Buenos Aires, BUE, Argentina
Site not named
Buenos Aires, BUE, Argentina
Site not named
Ciudad Autonoma de Bs. As., CBA, Argentina
Site not named
Ciudad Autonoma de Bs. As., CBA, Argentina
Site not named
Ciudad Autonoma de Bs. As., CBA, Argentina
Site not named
Rosario, SFE, Argentina
Site not named
San Miguel de Tucumán, TUC, Argentina
Site not named
Penrith, New South Wales, Australia
Site not named
Caboolture, Queensland, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Woodville, South Australia, Australia
Site not named
Launceston, Tasmania, Australia
Site not named
Ballarat, Victoria, Australia
Site not named
Fitzroy, Victoria, Australia
Site not named
Haskovo, Bulgaria, Bulgaria
Site not named
Plovdiv, Bulgaria, Bulgaria
Site not named
Rousse, Bulgaria, Bulgaria
Site not named
Sofia, Bulgaria, Bulgaria
Site not named
Sofia, Bulgaria, Bulgaria
Site not named
Barrie, Ontario, Canada
Site not named
Chatham, Ontario, Canada
Site not named
Hamilton, Ontario, Canada
Site not named
Richmond Hill, Ontario, Canada
Site not named
Sarnia, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Sherbrooke, Quebec, Canada
Site not named
Saskatoon, Saskatchewan, Canada
Site not named
Providencia, Chile, Chile
Site not named
Santiago, Chile, Chile
Site not named
Temuco, Chile, Chile
Site not named
Osijek, Croatia, Croatia
Site not named
Split, Croatia, Croatia
Site not named
Zagreb, Croatia, Croatia
Site not named
Tallinn, Estonia, Estonia
Site not named
Tallinn, Estonia, Estonia
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.